Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 1
1998 1
1999 4
2000 3
2001 6
2002 7
2003 4
2004 2
2005 7
2006 13
2007 6
2008 7
2009 11
2010 12
2011 15
2012 23
2013 9
2014 8
2015 11
2016 6
2017 8
2018 4
2019 3
2020 2
2021 2
2022 5
2023 2
2024 9
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

175 results

Results by year

Filters applied: . Clear all
Page 1
Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – April 2022 – AWMF-Registernummer: 021–025.
Roeb E, Canbay A, Bantel H, Bojunga J, de Laffolie J, Demir M, Denzer UW, Geier A, Hofmann WP, Hudert C, Karlas T, Krawczyk M, Longerich T, Luedde T, Roden M, Schattenberg J, Sterneck M, Tannapfel A, Lorenz P, Tacke F; Collaborators:. Roeb E, et al. Z Gastroenterol. 2022 Sep;60(9):1346-1421. doi: 10.1055/a-1880-2283. Epub 2022 Sep 13. Z Gastroenterol. 2022. PMID: 36100202 Free article. German. No abstract available.
Amendment „Neue Nomenklatur zur MASLD (Metabolic Dysfunction Associated Steatotic Liver Disease; metabolische Dysfunktion assoziierte steatotische Lebererkrankung)“ zur S2k-Leitlinie „Nicht-alkoholische Fettlebererkrankung“ (v.2.0/April 2022) der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS).
Roeb E, Canbay A, Bantel H, Bojunga J, de Laffolie J, Demir M, Denzer UW, Geier A, Hofmann WP, Hudert C, Karlas T, Krawczyk M, Longerich T, Lüdde T, Roden M, Schattenberg JM, Sterneck M, Tannapfel A, Lorenz P, Tacke F; Collaborators. Roeb E, et al. Z Gastroenterol. 2024 Jul;62(7):1077-1087. doi: 10.1055/a-2309-6052. Epub 2024 Jul 8. Z Gastroenterol. 2024. PMID: 38976985 German. No abstract available.
Modern pharmacological treatment of obese patients.
May M, Schindler C, Engeli S. May M, et al. Among authors: engeli s. Ther Adv Endocrinol Metab. 2020 Jan 22;11:2042018819897527. doi: 10.1177/2042018819897527. eCollection 2020. Ther Adv Endocrinol Metab. 2020. PMID: 32030121 Free PMC article. Review.
Prescriptions for Potentially Inappropriate Medication (PIM).
Wohlgemuth A, Michalowsky B, Hoffmann W, Platen M, Engeli S, Wucherer D, Ittermann T. Wohlgemuth A, et al. Among authors: engeli s. Dtsch Arztebl Int. 2024 Jan 12;121(1):25-26. doi: 10.3238/arztebl.m2023.0181. Dtsch Arztebl Int. 2024. PMID: 38386944 Free PMC article. No abstract available.
Apoptotic pathways in adipose tissue.
Herold C, Rennekampff HO, Engeli S. Herold C, et al. Among authors: engeli s. Apoptosis. 2013 Aug;18(8):911-6. doi: 10.1007/s10495-013-0848-0. Apoptosis. 2013. PMID: 23584726 Review.
New developments in the pathogenesis of obesity-induced hypertension.
Kotsis V, Nilsson P, Grassi G, Mancia G, Redon J, Luft F, Schmieder R, Engeli S, Stabouli S, Antza C, Pall D, Schlaich M, Jordan J; WG on Obesity, Diabetes, the High Risk Patient, European Society of Hypertension. Kotsis V, et al. Among authors: engeli s. J Hypertens. 2015 Aug;33(8):1499-508. doi: 10.1097/HJH.0000000000000645. J Hypertens. 2015. PMID: 26103132 Review.
175 results